Previsão

Não temos dados de analistas para esta empresa.

Notícias Ir para o feed de notícias

Implantica increases revenue by 66% after FDA approval for RefluxStop

Implantica reports net revenue of EUR 717,000 in Q2 2026, up 66% year-on-year, and an adjusted gross margin of 94%. US FDA approval for the RefluxStop device marks the shift to commercialization and enables planned staggered launches in the US. The company remains unprofitable with an operating loss of EUR 4.2 million, but holds EUR 41.7 million in cash and plans estimated investments of EUR 7–15 million annually for the US expansion. » Mais em de.investing.com
Implantica grows 66% after FDA approval and prepares US launch

Implantica increased net revenue in Q2 by 66% to 717.000 EUR and improved the adjusted gross margin to 94%, but remained unprofitable with an operating loss of 4.2 Mio. EUR. The FDA approval for the RefluxStop implant is seen as a turning point and paves the way for a phased market launch in the US; the company has produced 13.000 devices and reported more than 100 interested surgeons. Liquidity stands at 41.7 Mio. EUR, with no interest-bearing liabilities; estimated annual costs for the US launch are 7–15 Mio. EUR. Management plans to present further details on strategy and the five-year plan at the Capital Markets Day on 9 September. » Mais em de.investing.com
Implantica receives FDA approval for reflux implant RefluxStop

The US FDA has granted Implantica Premarket Approval (PMA) for the reflux implant RefluxStop, allowing the company to begin commercial rollout in the United States. The approval is based on five-year long-term data demonstrating safety and efficacy. Implantica plans a phased introduction in selected centers and with reflux surgeons; RefluxStop is already CE-certified and has been used in about 1,800 patients in Europe. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, IMPLANTICA AG SDR./1 registou receitas de € 707,45 mil e um ganho líquido de -€ 3,91 mi

(EUR)	junho de 2026	YoY
Receitas	707,45 mil	63,38%
Ganho bruto	312,78 mil	281,44%
Ganho líquido	-3,91 mi	27,89%
EBITDA	-3,79 mi	14,33%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 318,59 mi
Número de ações	58,38 mi
Máximo/mínimo de 52 semanas	€ 7,14 - € 3,38
Dividendos	Não
Beta	0,79
PER (PE Ratio)	-19,64
PEG (PEG Ratio)	0,22
P/VC (PB Ratio)	4,92
P/V (PS Ratio)	131,20

Perfil da empresa

Implantica AG, ein Medizintechnikunternehmen, erforscht, entwickelt und vertreibt medizinische Implantate für ungedeckte medizinische Bedürfnisse in der Schweiz. Der wichtigste Produktkandidat ist RefluxStop, ein passives, CE-gekennzeichnetes Implantat zur Prävention der gastroösophagealen Refluxkrankheit. Das Unternehmen entwickelt auch e-InVivo, ein Sensorimplantat zur Überwachung einer Vielzahl von Gesundheitsparametern und zur Bereitstellung von Diagnoseinformationen sowie zur Steuerung der Behandlung aus dem Körperinneren, eine drahtlose Energieplattform und AppetiteControl, ein Implantat zur Behandlung von Fettleibigkeit durch Appetitkontrolle. Darüber hinaus entwickelt es UriControl, ein ferngesteuertes Implantat zur Behandlung von Harninkontinenz bei Männern und Frauen, und UriRestor, ein ferngesteuertes Gerät, das es Patienten mit Rückenmarksverletzungen und MS ermöglicht, über die drahtlose Plattform bei Bedarf zu urinieren. Das Unternehmen wurde im Jahr 2015 gegründet und hat seinen Sitz in Vaduz, Liechtenstein. Die Implantica AG ist eine Tochtergesellschaft von Implantica MediSwiss.

Nome	IMPLANTICA AG SDR./1
CEO	Peter Forsell
Sede	Vaduz, va Suécia
Site	implantica.com
Setor	Cuidados de saúde
Indústria	Tecnologia de saúde
Entrada em bolsa	21/09/2020
Colaboradores	46